The long-term objective of this Project is to determine the natural history of monoclonal gammopathy of undetermined significance (MGUS). We will determine the prevalence of MGUS in Olmsted County, Minnesota and then follow asymptomatic prevalence cases as well as MGUS patients previously recognized clinically in a prospective study. To ascertain long-term outcome, we will also conduct a retrospective cohort study using clinically recognized mGUS patients. Although the quality of medical information in the Olmsted County population is excellent, the relatively small population (106,000) poses some problems in obtaining enough cases for determining the natural course of diseases of relatively low frequency. Therefore, we will expand the study population to include cases from the remaining 10 Southeastern Minnesota counties. This is justified by the similarity of MGUS patients in Olmsted County and Southeastern Minnesota on the basis of their age, sex, race, size and type of M-protein found in our earlier surveys. All cases of MGUS from the entire Southeastern Minnesota area diagnosed from 1956 through 1994 will be followed in a retrospective cohort study for survival and risk of multiple myeloma, macroglobulinemia, primary amyloidosis, and other plasma cell proliferative disorders. We will follow the survivors of the Southeastern Minnesota MGUS cohort that has been followed retrospectively and new cases recognized after January 1, 1995 annually in a prospective study to determine the factors associated with progression of MGUS to multiple myeloma and related disorders. This project will also provide bone marrow and peripheral blood to Projects II and III in order to investigate the molecular events in the transition of MGUS to multiple myeloma. This includes determination of IL-6, IL-1, and sIL-6R mRNA expression and serum levels of IL-6 and sIL-6R in patients with MGUS and active multiple myeloma (Project II). The studies described in Project III extend those of Project II by examining specific mechanisms that may account for increased IL-6 production by the tumor itself such as aberrant signaling and response to CD40 stimulation or deregulation of pRb1. The potential to study patients with MGUS that progress to myeloma from serial samples obtained through Project I will provide extremely valuable information about the role of Il-6 in the progression of MGUS to myeloma. Peripheral blood will be studied for the presence of circulating myeloma cells in both MGUS and MM (Project IV). Hopefully, a better understanding of the molecular events underlying the progression of MGUS will result in the development of approaches to interfere with this progression.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA062242-03
Application #
5209327
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Lwin, S T; Fowler, J A; Drake, M T et al. (2017) A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo. Mol Cancer 16:49
Gonsalves, W I; Rajkumar, S V; Dispenzieri, A et al. (2017) Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia 31:130-135
Mullikin, Trey C; Rajkumar, S Vincent; Dispenzieri, Angela et al. (2016) Clinical characteristics and outcomes in biclonal gammopathies. Am J Hematol 91:473-5
Gonsalves, Wilson I; Timm, Michael M; Rajkumar, S Vincent et al. (2016) The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leuk Res 44:32-9
Kaufman, Gregory P; Dispenzieri, Angela; Gertz, Morie A et al. (2015) Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol 90:181-6
Gonsalves, W I; Leung, N; Rajkumar, S V et al. (2015) Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J 5:e296
Cesarman-Maus, Gabriela; Braggio, Esteban; Lome-Maldonado, Carmen et al. (2014) Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. Thromb Res 133:606-9
Landgren, O; Graubard, B I; Katzmann, J A et al. (2014) Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia 28:1537-42
Kumar, S K; Dispenzieri, A; Lacy, M Q et al. (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122-8
Gonsalves, Wilson I; Rajkumar, S Vincent; Go, Ronald S et al. (2014) Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood 124:907-12

Showing the most recent 10 out of 365 publications